Neovasc has announced in a press release that its Tiara technology was featured in a “live case” broadcast to the 2015 Transcatheter Cardiovascular Therapeutics (TCT) symposium.
In the broadcast, which was displayed to the main arena of the conference, a 35mm Tiara transcatheter mitral valve was successfully implanted in a patient with severe mitral regurgitation (MR) by Anson Cheung and John Webb of St. Paul’s hospital, Vancouver, Canada. The implantation was successfully completed within thirty minutes, and with no procedural complications. The Tiara valve implantation completely resolved the patient’s MR.
“This live case broadcast reinforced Tiara’s potential as a new treatment option for patients with severe MR and who are at high risk for conventional surgery,” comments Neovasc chief executive officer, Alexei Marko. “Attending physicians were able to see first-hand the simplicity of the catheter-based implantation procedure and the resulting elimination of the patient’s MR. The TIARA-I Early Feasibility Study is continuing to enroll patients, in the U.S., Canada, and Belgium.”
